Skip to main content
Fig. 3 | The Journal of Headache and Pain

Fig. 3

From: Real-world effectiveness of fremanezumab in migraine patients initiating treatment in the United States: results from a retrospective chart study

Fig. 3

Effectiveness outcomes by proportion of patients with a ≥ 50% reduction from baseline in MMD: A) total population; B) dosing schedule subgroups; C) prior treatment failures subgroups. BL, baseline; MMD, monthly migraine days; Q, quarterly; M, monthly. aNumber of patients with available assessment at each time point

Back to article page

The Journal of Headache and Pain

ISSN: 1129-2377

Contact us